Niagen Bioscience (NAGE) announced it has entered into a worldwide exclusive commercial license agreement with Haukeland University Hospital in Bergen, Norway. The agreement secures exclusive rights to intellectual property, know-how, and data expected to support future regulatory filings for the potential treatment of Parkinson’s Disease using the company’s patented nicotinamide riboside molecule, Niagen. Central to the agreement is access to data from the NOPARK trial, a Phase III clinical trial featuring 400 individuals with early-stage Parkinson’s.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience Approves Equity Plan Amendment
- Niagen Bioscience price target raised to $16 from $13 at Canaccord
- Niagen Bioscience presents results in journal Aging Cell
- Niagen Bioscience price target raised to $23 from $10 at Roth Capital
- Canaccord starts Niagen Bioscience at Buy on ‘unique opportunity’